MARKET

EDIT

EDIT

Editas Medicine
NASDAQ

Real-time Quotes | Nasdaq Last Sale

31.62
+0.14
+0.44%
After Hours: 31.62 0 0.00% 16:34 07/14 EDT
OPEN
31.01
PREV CLOSE
31.48
HIGH
32.06
LOW
30.30
VOLUME
1.04M
TURNOVER
--
52 WEEK HIGH
36.78
52 WEEK LOW
14.01
MARKET CAP
1.94B
P/E (TTM)
-11.4383
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average EDIT stock price target is 38.88 with a high estimate of 55.00 and a low estimate of 27.00.

EPS

EDIT News

More
What You Need To Know About Editas Medicine, Inc.'s (NASDAQ:EDIT) Investor Composition
Simply Wall St. · 2d ago
3 Top Biotech Stocks to Watch in July
MotleyFool.com · 5d ago
Editas Medicine and Azzur Group Announce a Multi-year Agreement for EDIT-301 and EDIT-201 Manufacturing
GlobeNewswire · 07/07 14:00
Editas Medicine, Azzur Group Announce Multi-Year Agreement For EDIT-301, EDIT-201 Manufacturing; No Terms Disclosed
Editas Medicine and Azzur Group Announce a Multi-year Agreement for EDIT-301 and EDIT-201 Manufacturing CAMBRIDGE, Mass., and WALTHAM, Mass., July 07, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a
Benzinga · 07/07 13:01
Better Buy: Editas Medicine vs. Intellia
Motley Fool · 07/02 16:32
Cellectis Starting To Look Like A Biotech Buy
Seeking Alpha - Article · 06/29 17:35
Do Hedge Funds Love Editas Medicine, Inc. (EDIT)?
Insider Monkey · 06/28 03:20
Editas Medicine Announces Closing of Offering of Common Stock and Full Exercise by Underwriter of Option to Purchase Additional Shares
GlobeNewswire · 06/26 21:05

Industry

Biotechnology & Medical Research
+2.50%
Pharmaceuticals & Medical Research
+1.66%

Hot Stocks

Symbol
Price
%Change

About EDIT

Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).
More

Webull offers kinds of Editas Medicine Inc stock information, including NASDAQ:EDIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDIT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EDIT stock methods without spending real money on the virtual paper trading platform.